P53 deletion may drive the clinical evolution and treatment response in multiple myeloma

47Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

We report a patient with multiple myeloma presenting with a paraspinal plasmacytoma with a marked dissociation between the response obtained in bone marrow (BM) infiltration and that achieved in soft tissue masses. While a complete remission was reached and maintained in BM, extramedullary plasmacytomas were refractory to every line of treatment. Genetic analysis identified the presence of t(4;14) and RB deletion in myeloma cells of both origins. However, a P53 deletion was only detected in plasma cells from extramedullary plasmacytomas. This finding suggests that P53 deletion has a role in the lack of treatment response of extramedullary plasmacytomas. © 2010 John Wiley & Sons A/S.

Author supplied keywords

Cite

CITATION STYLE

APA

López-Anglada, L., Gutiérrez, N. C., García, J. L., Mateos, M. V., Flores, T., & San Miguel, J. F. (2010). P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. European Journal of Haematology, 84(4), 359–361. https://doi.org/10.1111/j.1600-0609.2009.01399.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free